Physician profile
Thomas D Spera
NPI 1326030032
$4,114.22
in general payments reported to CMS, 2019-2025
13 companies · $674 in 2025
The $674 reported for 2025 was more than what 82% of Diagnostic Radiology providers received nationally (typical 2025 total: $112).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,522 · 2020: $111 · 2021: $183 · 2022: $75.96 · 2023: $267 · 2024: $281 · 2025: $674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,221.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $1,807.63 | 2019-2025 | Penumbra System, Indigo System, Ruby Coil |
| Medtronic Vascular, INC. | $861.46 | 2019-2020 | |
| Medtronic, INC. | $443.55 | 2023-2025 | Concertotm, In.Pact Admiral, Hawkone |
| Bard Peripheral Vascular, INC. | $249.37 | 2020-2024 | Venovo, Lutonix Drug Coated Balloon, Trek |
| Philips North America LLC | $220.11 | 2019-2024 | (Br5) Peripheral Ivus |
| Inari Medical, INC. | $195.05 | 2021-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Argon Medical Devices, INC. | $134.36 | 2025 | Clot Management |
| Karyopharm Therapeutics INC. | $81.88 | 2023 | Xpovio |
| Abbott Laboratories | $50.68 | 2019 | |
| Cook Medical LLC | $27.37 | 2023 | Cook Celect, Cook |
| Boston Scientific Corporation | $17.34 | 2021 | |
| Seagen INC. | $13.78 | 2023 | Adcetris |
| Angiodynamics, INC. | $11.64 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Spera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.